GSK's Trelegy On Track To Be First Triple Inhaled Regimen For Asthma
The company filed an sNDA with the US FDA for the triple combination, hoping to expand its current COPD indication to also include asthma.
You may also be interested in...
The company is keeping up the pressure on GSK, getting approval for self-administration for Fasenra a few months after a similar green light for severe asthma rival Nucala.
R&D President Hal Barron outlined progress reenergizing GSK's pharma pipeline and highlighted the key milestones ahead in 2019 during the company's second quarter call.
Mylan's generic version of GlaxoSmithKline's blockbuster asthma drug was approved by the US FDA Jan. 30. Scrip's timeline tracks how the commercial value of the drug for GSK has greatly declined from its peak in 2013.